Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc)(Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc))

概要

基本信息

药物类型

灭活疫苗、联合疫苗、预防性疫苗

+ [1]

别名

Boostrix、dTpa vaccine、Refortrix

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病其他疾病

在研适应症

白喉破伤风百日咳

非在研适应症-

原研机构

GSK Plc

在研机构

GlaxoSmithKline GmbH & Co. KG

GSK PlcGlaxoSmithKline LLC

+ [1]

非在研机构-

权益机构

GSK Plc

SK bioscience Co., Ltd.

最高研发阶段批准上市

首次获批日期

奥地利 (2000-10-03),

白喉破伤风百日咳

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

关联

52

项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的临床试验

JPRN-jRCT2031260190

/ Recruiting临床3期

A Phase 3, non-randomized, single-arm, open-label study to assess the immunogenicity, safety and reactogenicity of a single dose of combined reduced-antigen-content diphtheria, tetanus and acellular pertussis (dTpa) vaccine in Japanese healthy pregnant women.

开始日期2026-06-29

申办/合作机构

GlaxoSmithKline KK

NCT07596173

/ Completed临床3期

A Phase 3, Non-randomized, Single-arm, Open-label Study to Assess the Immunogenicity, Safety and Reactogenicity of Combined Reduced-antigen-content Diphtheria, Tetanus and Acellular Pertussis (dTpa) Vaccine, Administered as a Booster Dose in Healthy Japanese Adolescents Aged 11 Years to <13 Years

The purpose of the study is to assess the immune response, reactogenicity and safety of a booster dose of dTpa vaccine 1 month after vaccination in healthy Japanese participants aged 11 to <13 years.

开始日期2026-06-29

申办/合作机构

GSK Plc

JPRN-jRCT2031260187

/ Recruiting临床3期

A Phase 3, non-randomized, single-arm, open-label study to assess the immunogenicity, safety and reactogenicity of combined reduced-antigen-content diphtheria, tetanus and acellular pertussis (dTpa) vaccine, administered as a booster dose in healthy Japanese adolescents aged 11 years to <13 years.

开始日期2026-06-29

申办/合作机构

GlaxoSmithKline KK

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

125

项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的文献（医药）

2026-06-01·LANCET INFECTIOUS DISEASES

Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial

Article

作者: Berlanda Scorza, Francesco ; Nigro, Simona ; Rondini, Simona ; De Coster, Ilse ; Massai, Luisa ; Conti, Valentino ; Rossi, Omar ; La Gaetana, Rita ; Serry-Bangura, Alimamy ; Luna Cilio, Giulia ; AbdelGhany, Mohammad ; Fineschi, Chiara ; Withanage, Kanchanamala ; Carducci, Martina ; Van Damme, Pierre ; Tessitore, Pietro ; Nakakana, Usman N ; Micoli, Francesca ; Sarakinou, Eleanna ; Kumar Arora, Ashwani ; Marchetti, Elisa

BACKGROUND:

Enteric fever caused by Salmonella enterica serovars Typhi and Paratyphi A remains a major concern. No vaccines are licensed against Salmonella Paratyphi A. We aimed to assess the safety and immunogenicity of an investigational conjugate vaccine against Salmonella Typhi and Paratyphi A (Vi-CRM₁₉₇+O:2-CRM₁₉₇).

METHODS:

In this observer-masked, randomised, controlled, dose-escalation, single-centre, phase 1 trial done during Nov 28, 2022, to April 2, 2024, at the Centre for Evaluation of Vaccination in Belgium, healthy adults (aged 18-50 years) were randomly assigned (2:1 or 2:2:1 across different steps using sealed envelopes following a randomisation schedule generated by an independent statistician) to receive two intramuscular doses (on day 1 and day 169) of one of four Vi-CRM₁₉₇+O:2-CRM₁₉₇ formulations (low dose or full dose, with or without aluminium hydroxide) or a control vaccine (Vi capsular polysaccharide vaccine and diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine for first and second dose). The primary outcome was vaccine safety (solicited events during 7 days and unsolicited adverse events during 28 days after vaccination, serious adverse events [SAEs], and adverse events or SAEs leading to study withdrawal or withholding of further study intervention administration from day 1 to day 197, and deviations from normal or baseline laboratory test values 7 days after vaccination). Secondary outcomes included long-term vaccine safety (SAEs and adverse events or SAEs leading to study withdrawal from day 197 to day 337), and immunogenicity, including anti-Vi and anti-O:2 IgG antibody geometric mean concentrations and geometric mean ratios (GMRs) by ELISA, and seroresponses (percentages of participants with anti-Vi IgG concentrations ≥4·3 μg/mL and ≥2·0 μg/mL; ≥4-fold anti-O:2 IgG concentration increase from baseline) at day 1 (as applicable), day 29, day 169, day 176, and day 197. Safety analyses were done on the solicited safety set, unsolicited safety set, and the exposed set. The primary immunogenicity analysis was done on the per-protocol set defined by timepoint. The trial is registered with ClinicalTrials.gov (NCT05613205) and gsk-studyregister.com (205480), and is completed.

FINDINGS:

96 participants were randomly assigned, 12 to each low-dose group, 24 to each full-dose group, and 24 to the control group. The incidence of solicited administration-site events (mostly pain) ranged from six (50% [95% CI 21·1-78·9]) of 12 participants in the low-dose without aluminium hydroxide group to 23 (96% [78·9-99·9]) of 24 in the full-dose with aluminium hydroxide group, versus 22 (92% [73·0-99·0]) of 24 in the control group. Solicited systemic events (mostly fatigue, headache, and myalgia) ranged from eight (67% [34·9-90·1]) of 12 in the low-dose groups to 20 (83% [62·6-95·3]) of 24 in the full-dose with aluminium hydroxide group, versus 21 (88% [67·6-97·3]) of 24 in the control group. The incidence of unsolicited adverse events (mostly nasopharyngitis) ranged from seven (58% [27·7-84·8]) of 12 in the low-dose without aluminium hydroxide group to ten (83% [51·6-97·9]) of 12 in the low-dose with aluminium hydroxide group, versus 14 (58% [36·6-77·9]) of 24 in the control group. Most safety laboratory results were within reference ranges. No SAEs occurred. After dose 1 (ie, at day 29), full-dose without aluminium hydroxide and full-dose with aluminium hydroxide induced the highest anti-Vi IgG responses (GMR 53·01 [95% CI 31·94-87·99] and 31·55 [18·74-53·11], respectively) versus control (4·50 [2·93-6·90]). Full-dose without aluminium hydroxide and low-dose without aluminium hydroxide induced the highest anti-O:2 IgG responses after dose 1 (GMR 162·61 [91·17-290·04] and 114·19 [44·83-290·86], respectively), versus control (1·27 [1·02-1·60]). 89-100% and 82-100% of participants (lowest percentages for low-dose with aluminium hydroxide) had anti-Vi IgG ≥4·3 μg/mL at day 29 (in initially seronegative participants) and ≥4-fold anti-O:2 IgG increase from baseline, respectively, versus 13 (54% [95% CI 32·8-74·4]) and one (4% [0·1-21·1]) of 24 participants in the control group, respectively. The second dose did not boost the responses.

INTERPRETATION:

Vi-CRM₁₉₇+O:2-CRM₁₉₇ formulations did not raise safety concerns and showed immunogenicity with a single dose, supporting further clinical assessment of the full-dose without aluminium hydroxide in target populations (infants and older age groups) in endemic regions.

FUNDING:

Wellcome Trust.

2025-12-31·Human Vaccines & Immunotherapeutics

Economic evaluation of the second booster dose of diphtheria-tetanus-acellular pertussis vaccine for children aged 6 years in Zhejiang Province: A cost-utility analysis

Article

作者: Zheng, Shuhan ; Zhou, Yang ; Su, Ying ; He, Hanqing ; Zhu, Yao ; Luo, Feng ; Tang, Xuewen

Despite increasing pertussis breakthroughs and waning immunity, this study evaluates the cost-effectiveness of replacing the DT booster with DTaP in 6-year-olds in Zhejiang, China. While implemented in high-income regions, this strategy's cost-effectiveness remains unassessed in diverse Chinese settings. We address this gap using local data.Using surveillance data from the Zhejiang Provincial Center for Disease Control and Prevention, literature reviews, and a 10-year simulation timeframe, a decision tree-Markov model was constructed from a societal perspective. The study cohort was 6-year-old children in Zhejiang Province in 2022. Comprehensive evaluation indicators, including Incremental Cost Effectiveness Ratio (ICER) and Incremental Cost-Utility Ratio (ICUR), were used. Robustness was assessed via Deterministic Sensitivity Analysis (DSA) and Probabilistic Sensitivity Analysis (PSA). Simulating 10 years after implementing the DTaP strategy for 628,619 children in 2022, under lower background incidence, DTaP could prevent 1,886 pertussis cases, reduce costs by 1.7 billion CNY, and gain 0.09 QALYs (ICUR = 3,096.15 CNY/QALY). Under higher incidence, it could prevent 8,743 cases, reduce costs by 1.6 billion CNY, and gain 0.084 QALYs (ICUR = 3,081.86 CNY/QALY). Both ICUR values are significantly lower than Zhejiang's per capita GDP (118,496 CNY). Our findings indicate that administering a second booster dose of DTaP to 6-year-old children is cost-effective, particularly with high incidence of pertussis.

2025-11-01·VACCINE

Immunogenicity and safety of co-administration of sabin-strain-based inactivated poliovirus vaccine, diphtheria-tetanus-acellular pertussis vaccine, and live attenuated hepatitis A vaccine in 18-month-old children: A multicenter randomized controlled non-inferiority trial in China

Article

作者: Chang, Shaoying ; Shi, Xuanwen ; Guo, Yu ; Liu, Xiaoyu ; Wang, Hui ; Wang, Yinan ; Zhang, Shaobai ; Hu, Weijun ; Wang, Ruize ; Han, Shasha ; Zhang, Dan ; Sun, Li ; Chen, Haiping ; Zhang, Chao ; Chen, Xiao

BACKGROUND:

Frequent healthcare visits increase children's risk of cross-infection. In both routine and emergency settings settings, co-administering vaccines or using combination vaccines can improve coverage, compliance, and timeliness. Vaccination is among the most cost-effective public health measures, with high coverage being critical for success, minimal immune interference, and improved programmatic efficiency.

METHODS:

This multicenter, randomized, open-label, non-inferiority phase IV trial extended a prior study (NCT04053010) to evaluate the immunogenicity and safety of co-administering sIPV, DTaP, and HepA-L in healthy Chinese children aged 18 months. Among 600 planned participants, 593 were enrolled and randomized (1:1:1:1) between November 2020 and January 2021: Group 1 (n = 148) received sIPV, DTaP, and HepA-L concomitantly; Groups 2/3/4 (n = 148/148/149) received sIPV, DTaP, or HepA-L separately as comparator controls. Immunogenicity non-inferiority was assessed via adjusted geometric mean ratios (co-ad group vs. sep-ad group per antigen) for poliovirus types I/II/III, DTaP components (DT, TT, PT, FHA), and HepA-L, with a prespecified margin of 0.67 for the 95 % CI lower bound. Antibody titers were assessed at baseline and 30 days post-vaccination: Poliovirus neutralizing antibodies (CPE method; reciprocal ND₅₀ titer), DTaP antibodies (ELISA; IU/mL), HepA-L IgG (electrochemiluminescence immunoassay; IU/L). Safety was monitored for 6 months after vaccination to record any adverse events or serious adverse events.

RESULTS:

Co-administration demonstrated non-inferior immunogenicity compared to separate administration for all antigens: polio types I (1271.21 vs. 1255.79), II (1915.91 vs. 2076.62), III (2306.41 vs. 2416.62); diphtheria (3.52 vs 3.31 IU/mL), pertussis toxoid (53.87 vs. 64.11 IU/mL); filamentous hemagglutinin (36.02 vs. 35.73 IU/mL), tetanus (9.23 vs 9.08 IU/mL), and hepatitis A (513.24 vs. 439.25 IU/L). Adverse event rates were comparable. Within 30 days post-vaccination, the overall adverse reaction (AR) incidence was higher in the co-administration group (11.49 %) than in Group 4 (4.70 %; P = 0.032) but was comparable to that in Group 2 (9.46 %) and Group 3 (6.08 %). Solicited local reactions occurred at similar rates across groups, with induration and redness being the most frequent. Similarly, fever was the predominant systemic reaction. Most ARs were Grade 1-2 in severity; Grade 3 events were rare (≤1.35 % across groups). No vaccine-related serious adverse events were reported.

CONCLUSION:

Simultaneous sIPV+DTaP+HepA-L administration is immunologically non-inferior and exhibits an acceptable safety profile, supporting its potential integration to optimize immunization programs.

CLINICAL TRIAL REGISTRATION:

https://clinicaltrials.gov/study/NCT04636827?cond=NCT04636827&rank=1-ID:NCT04636827.

28

项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的新闻（医药）

2026-08-19

·摩熵医药

国内首款！康希诺百白破疫苗，冲刺上市

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 8月14日，康希诺生物研发的吸附无细胞百（五组分）白破联合疫苗（适用6岁及以上人群，简称Td5cp）上市申请获国家药监局药品审评中心（CDE）正式受理。该产品成为国内首款进入上市申报阶段的青少年及成人用百白破加强疫苗，有望填补我国6岁以上人群百白破加强免疫领域的市场空白。截图来源：CDE官网 01 五组分设计，进一步提升抗原覆盖能力所谓“五组分”，是指疫苗包含5种百日咳抗原成分，包括百日咳毒素（PT）、丝状血凝素（FHA）、百日咳黏附素（PRN），以及菌毛蛋白2和3（Fim2/3）。与国内目前多数采用共纯化工艺的百白破疫苗不同，康希诺采用组分化生产工艺，对各抗原进行独立纯化，再按照固定比例进行配制，理论上能够实现更好的批间一致性和抗原质量控制。值得关注的是，Td5cp并非康希诺在百白破领域的首次布局。 2026年4月，康希诺婴幼儿用三组分百白破疫苗“盼康欣”获批上市，并于8月12日完成首批批签发，正式进入市场供应。截图来源：摩熵医药全球药物研发数据库（查数据.找摩熵）此次申报的Td5cp，则是在原有三种抗原基础上新增Fim2和Fim3两种菌毛蛋白，进一步扩大抗原覆盖范围。 02 对标国际成熟市场，填补国内免疫空白目前，全球青少年及成人百白破加强疫苗（Tdap）市场已较为成熟。葛兰素史克（GSK）的Boostrix和赛诺菲的Adacel是两款主流产品，但目前均尚未进入中国市场。相比之下，我国现行百白破免疫程序主要覆盖3月龄至6岁儿童，6岁以上人群缺乏常规加强免疫手段。因此，康希诺Td5cp此次申报上市，不仅是在补齐国内青少年及成人百白破加强免疫环节，也是在向国际成熟免疫接种体系靠拢。 03 国内竞争仍处早期，康希诺抢占先发优势从国内研发进展来看，同类产品虽已陆续进入临床阶段，但目前尚无其他产品进入上市申报。其中：康泰生物全资子公司北京民海生物的吸附无细胞百白破（组分）联合疫苗（成人青少年及儿童用）于2026年4月获批临床；智飞生物全资子公司北京智飞绿竹的青少年及成人用组分百白破疫苗于2025年11月获批临床；中国医学科学院医学生物学研究所开发的吸附组分无细胞百白破（减剂量）联合疫苗（Tdacp）于2026年2月进入Ⅱ期临床试验。该试验为随机、双盲、平行对照设计，旨在评价该疫苗在6岁及以上人群中接种的安全性和免疫原性。截图来源：摩熵医药全球药物研发数据库（查数据.找摩熵）从上市申报进度来看，康希诺Td5cp已形成明显领先优势，预计领先国内同行约3～5年。 04 多款疫苗布局，商业化压力仍待释放除百白破疫苗外，康希诺布局的吸附破伤风疫苗也提交了上市申请。该产品于2023年5月首次申请临床，2025年1月首次申请上市。2025年3月，康希诺与远大生命科学达成大中华区独家商业化合作，产品获批后由远大生命科学负责推广，预计2026年获批。截图来源：摩熵医药全球药物研发数据库（查数据.找摩熵）截至目前，摩熵医药数据显示，康希诺已有6款产品在全球获批上市，包括吸附无细胞百（三组分）白破联合疫苗、13价肺炎球菌多糖结合疫苗、重组新型冠状病毒疫苗、ACYW135群脑膜炎球菌结合疫苗等。截图来源：摩熵医药全球药物研发数据库（查数据.找摩熵）不过，业绩端压力仍然存在。康希诺尚未披露2026年半年报。今年一季度，公司实现营业收入1.90亿元，同比增长38.73%，但归母净利润亏损4042.43万元。随着百白破产品矩阵逐步完善，Td5cp能否成为公司新的增长曲线，仍需等待后续商业化表现验证。 END 本文为原创文章，转载请留言获取授权点击阅读原文，申请摩熵医药企业版免费试用！

2026-03-11

·EINPresswire

Whooping Cough Continues Wyoming Spread

March 11, 2026 Wyoming Department of Health (WDH) officials are concerned about the ongoing, active spread of pertussis (whooping cough) across the state. Kaylyn Friesen, vaccine-preventable disease epidemiologist with WDH, said there have been 26 confirmed pertussis cases in Wyoming so far this year. “While roughly two-thirds of the reported cases have been among Fremont County residents, pertussis has also been identified in other counties,” Friesen said. Friesen noted that 148 cases were reported in Wyoming in 2025, the highest since 1951. “We are continuing to see outbreaks and high monthly case counts,” Friesen said. Actual case numbers are likely higher because many illnesses are not recognized as pertussis, and others may not be reported. Pertussis typically begins with cold-like symptoms and perhaps a mild cough. Pertussis is often not suspected or diagnosed until a persistent cough with spasms develops after 1 to 2 weeks. Infants and children can cough violently and rapidly with a loud “whooping” sound. Dr. Alexia Harrist, state health officer with WDH, said, “One-third of infants less than 1 year of age who become ill with pertussis need to be hospitalized, and we know, in some cases, it can be deadly for these babies. Pertussis in the youngest babies can cause them to have pauses in breathing. Infants are simply more vulnerable and don’t yet have all the protection pertussis vaccines offer.” Harrist said the Tdap adolescent/adult pertussis booster vaccine is especially important for those spending time with new infants, such as parents, grandparents, and other people who take care of them. “Also, if you are pregnant or planning on becoming pregnant, you should talk to your doctor about a Tdap vaccine because that can also help protect newborns,” she said. Harrist recommends that all residents stay up to date with pertussis vaccines, as those who still become ill with pertussis after vaccination are less likely to have a severe experience. “In addition, people should consider seeing a medical professional for antibiotics if they have symptoms consistent with pertussis,” she said. More information about pertussis can be found online at https://health.wyo.gov/publichealth/infectious-disease-epidemiology-unit/disease/pertussis/ . Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

疫苗

2026-01-09

·drugs

Maternal Flu, Tdap Shots May Lower Rates of Infant Hospitalization, ED Visits

FRIDAY, Jan. 9, 2026 -- Maternal influenza and tetanus-diphtheria-acellular pertussis (Tdap) vaccinations are associated with a lower risk for influenza- and pertussis-related hospitalization or emergency department (ED) visits in infants younger than 6 months, according to a study published online Jan. 8 in JAMA Network Open . Gabriella Morabito, from the National Centre for Healthcare Research and Pharmacoepidemiology at the University of Milano-Bicocca Milan in Italy, and colleagues conducted a population-based cohort study using health care utilization databases from the Lombardy region of Italy to examine the association of maternal influenza and Tdap vaccinations with influenza- and pertussis-related hospitalizations and ED visits among infants aged younger than 6 months. A total of 53,448 pregnant individuals who received the Tdap vaccine and 5,347 who received the influenza vaccine were included in the study. Maternal vaccination coverage was 6.4 and 41.0 percent for influenza and Tdap, respectively. The researchers found that the risk for hospitalization or ED visits for influenza and pertussis was lower among infants born to mothers who received the influenza and Tdap vaccines (vaccine effectiveness, 69.7 and 88.6 percent, respectively). "These results support the current recommendations for administering these vaccines during pregnancy and highlight the urgent need to implement strategies aimed to increase their acceptance," the authors write. One author disclosed ties to the pharmaceutical industry. Abstract/Full Text

疫苗临床结果

100 项与 Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07CA02	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
白喉	奥地利	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	比利时	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	保加利亚	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	克罗地亚	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	塞浦路斯	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	捷克	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	丹麦	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	爱沙尼亚	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	芬兰	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	法国	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	德国	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	希腊	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	匈牙利	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	冰岛	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	爱尔兰	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	意大利	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	拉脱维亚	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	立陶宛	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	卢森堡	GlaxoSmithKline GmbH & Co. KG	2000-10-03
白喉	马耳他	GlaxoSmithKline GmbH & Co. KG	2000-10-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00505063 (CTgov)	临床2期	实体瘤 \| 肿瘤 \| 多发性硬化症 ... 更多	75	Hib+Prevnar 13+Pediarix (Cohort A)	膚觸艱範窪網衊觸積餘 = 醖襯鏇糧繭鬱網餘鹽鬱範鬱鬱艱鬱製觸觸獵遞 (艱艱網醖鬱夢選膚鹽鏇, 憲襯觸齋顧襯鹹廠壓艱 ~ 憲糧齋憲蓋廠鹹蓋鹹築) 更多	-	2026-07-29
				Prevnar 13 #1+Prevnar 13 (Cohort B)	膚觸艱範窪網衊觸積餘 = 壓鏇餘觸蓋積繭鹹鏇淵範鬱鬱艱鬱製觸觸獵遞 (艱艱網醖鬱夢選膚鹽鏇, 遞鹽築齋築糧簾製觸觸 ~ 壓壓糧積築窪憲築構憲) 更多
NCT05169905 (CTgov)	临床3期	呼吸道合胞体病毒感染	9	RSV MAT vaccine+dTpa vaccine (RSV_dTpa-P Group)	窪醖願選願廠窪選觸醖 = 襯築顧餘選夢鹽鏇醖襯夢鏇夢醖憲鑰餘鏇壓蓋 (憲鹹積網築鬱廠鹽蓋艱, 構衊製餘襯鹹繭鑰選醖 ~ 廠鹽鹹衊鑰顧範憲範製) 更多	-	2023-04-07
				RSV MAT vaccine+dTpa vaccine (RSV_dTpa-A Group)	窪醖願選願廠窪選觸醖 = 餘襯蓋夢膚衊夢餘構鏇夢鏇夢醖憲鑰餘鏇壓蓋 (憲鹹積網築鬱廠鹽蓋艱, 淵壓膚餘構鏇襯餘夢廠 ~ 襯構範夢遞廠蓋選廠選) 更多
NCT03589768 (CTgov)	临床2期	白喉 \| 百日咳 \| 艰难梭菌结肠炎 ... 更多	399	BOOSTRIX (BOOSTRIX - Maternal)	憲鹽窪醖膚選積構齋襯 = 壓餘憲遞憲淵蓋憲淵鬱獵選築齋壓夢齋獵艱選 (壓壓餘製簾醖願夢遞積, 蓋窪憲蓋糧艱網襯簾顧 ~ 鹽糧遞繭襯範廠鹽鑰衊) 更多	-	2023-01-20
				Td (Td - Maternal)	憲鹽窪醖膚選積構齋襯 = 鏇積選網鬱顧醖遞糧鬱獵選築齋壓夢齋獵艱選 (壓壓餘製簾醖願夢遞積, 鏇醖糧蓋餘鹹網鹹製醖 ~ 遞衊淵獵鑰膚鏇網醖醖) 更多
NCT03311659 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	448	Boostrix	獵範膚範窪壓憲廠衊觸 = 鬱窪簾壓壓窪淵壓繭繭鑰鏇醖構獵蓋衊獵願鬱 (獵憲選顧獵艱願觸範壓, 壓襯糧鹹鑰鏇鹹遞夢齋 ~ 製網築獵窪醖襯顧網鹽) 更多	-	2019-10-23
NCT02377349 (CTgov)	临床4期	白喉 \| 百日咳 \| 破伤风	688	dTpa (dTpa Group - Mother)	鹹鹽獵衊憲簾糧壓鏇窪(製齋範範簾鏇顧窪鏇築) = 鹹獵顧選蓋積襯齋網簾鬱艱遞範製鹹艱鹹蓋鹹 (艱範積願簾鬱鏇築觸夢, 艱積遞網鹽顧餘鹹餘鹹 ~ 觸憲鹹衊齋衊夢糧鏇壓) 更多	-	2019-01-28
				placebo+Boostrix (Control Group - Mother)	鹹鹽獵衊憲簾糧壓鏇窪(製齋範範簾鏇顧窪鏇築) = 網襯鬱鹽構築簾積範積鬱艱遞範製鹹艱鹹蓋鹹 (艱範積願簾鬱鏇築觸夢, 廠構襯顧夢襯齋夢鹹蓋 ~ 選壓窪衊願簾糧觸範襯) 更多
NCT00548171 (CTgov)	临床4期	白喉 \| 百日咳 \| 破伤风	203	Boostrix™ (Boostrix I Group)	廠衊觸糧憲鏇觸築選遞 = 簾簾積鬱糧鹹蓋築餘艱築鏇築鏇蓋鏇積積鬱選 (夢鹹膚醖鬱襯艱淵壓醖, 積壓憲壓觸鹹齋衊範選 ~ 積窪廠獵遞壓廠選廠鹹) 更多	-	2019-01-15
				Boostrix™ (Boostrix II Group)	廠衊觸糧憲鏇觸築選遞 = 簾顧鹽衊獵蓋襯夢顧選築鏇築鏇蓋鏇積積鬱選 (夢鹹膚醖鬱襯艱淵壓醖, 廠構齋鬱繭選壓襯網構 ~ 獵齋憲鹹鏇網遞遞觸糧) 更多
NCT00385255 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	1,726	Fluarix®+Boostrix® (Boostrix+Fluarix Group)	窪觸淵醖夢窪醖積齋膚(憲願觸簾選簾鏇簾艱願) = 醖齋餘蓋繭網遞鹹醖鏇範顧製鏇築製窪廠獵蓋 (築觸觸蓋糧膚淵憲鹹憲, 網積範衊製觸鬱艱夢窪 ~ 衊憲鬱鹹觸鏇觸壓糧範) 更多	-	2018-09-17
				Fluarix®+Boostrix® (Fluarix Boostrix Group)	窪觸淵醖夢窪醖積齋膚(憲願觸簾選簾鏇簾艱願) = 膚壓範糧醖選簾齋製衊範顧製鏇築製窪廠獵蓋 (築觸觸蓋糧膚淵憲鹹憲, 鹽構蓋糧獵選鹹壓鏇窪 ~ 餘壓醖製鹽繭積齋醖艱) 更多
NCT00346073 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	2,337	Boostrix™ (Boostrix Group)	壓襯襯顧築願糧簾築築 = 衊窪壓簾製膚艱範淵襯積鏇齋憲醖構窪構醖獵 (選顧夢淵簾膚願簾選膚, 遞壓淵築淵淵鏇製壓鑰 ~ 構淵築顧鹽襯範鏇壓鹽) 更多	-	2018-08-07
				ADACEL® (Adacel Group)	壓襯襯顧築願糧簾築築 = 鹹鏇餘鏇鬱積鏇艱繭壓積鏇齋憲醖構窪構醖獵 (選顧夢淵簾膚願簾選膚, 顧鏇齋衊顧夢餘選壓遞 ~ 鑰繭壓膚繭鏇憲鹹壓簾) 更多
NCT01755689 (Pubmed \| Vaccine) 人工标引	临床3期	脑膜炎球菌感染	1,300	MenACWY-TT+human papillomavirus 16/18 AS04-adjuvanted vaccine+tetanus-diphtheria-acellular pertussis vaccine	願廠餘鏇構襯鑰蓋糧蓋(遞築築範構鬱廠範淵糧) = No safety concerns were identified 網餘齋淵艱廠壓壓積獵 (願鹽餘鹽繭積積構餘糧 ) 更多	积极	2018-06-22
NCT01738477 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	165	Boostrix (Boostrix Group 1)	鑰製醖觸夢膚獵製顧憲 = 範餘構製鑰鏇遞顧憲網範鬱網願繭鑰憲觸襯選 (簾齋餘襯膚顧製餘衊積, 醖糧鑰壓鹽製鏇網鹹蓋 ~ 襯積製遞鏇範憲網製壓) 更多	-	2017-12-27
				Boostrix (Boostrix Group 2)	鑰製醖觸夢膚獵製顧憲 = 艱簾蓋顧範遞淵願齋鹹範鬱網願繭鑰憲觸襯選 (簾齋餘襯膚顧製餘衊積, 範糧夢繭醖憲糧鬱製餘 ~ 衊鑰襯夢顧壓製網艱繭) 更多